Whether integration costs were sandbagged in the CIM from regulatory-approval

Situation

Integration costs were sandbagged sits with customer-contract risk reviewer because a founder who will not sign a non-compete hit a cross-border deal with earnout-heavy structure. Evidence is regulatory-approval critical-path calendar; write the M&A Due Diligence Earnings and Revenue Quality option that extract can carry.

Decision

Customer-contract risk reviewer in a cross-border deal with earnout-heavy structure must choose Proceed / Reprice / Walk / Hold using regulatory-approval critical-path calendar after a founder who will not sign a non-compete.

Hypotheses to test

• The population in regulatory-approval critical-path calendar is the one a founder who will not sign a non-compete named, so Proceed follows for this Earnings and Revenue Quality file.
• The population in regulatory-approval critical-path calendar is adjacent only to a founder who will not sign a non-compete; Reprice is the honest M&A Due Diligence call.
• A cross-border deal with earnout-heavy structure already contained a founder who will not sign a non-compete before regulatory-approval critical-path calendar arrived; no new Earnings and Revenue Quality path.
• Provenance on regulatory-approval critical-path calendar after a founder who will not sign a non-compete is broken; do not pick Proceed or Reprice yet.

Analysis required

• Separate a one-off add-back from a recurring earnings issue in regulatory-approval critical-path calendar.
• Map reps, earnout mechanics, and integration risk a cross-border deal with earnout-heavy structure would inherit.
• Tie quality-of-earnings, working-capital, and contingent items in regulatory-approval critical-path calendar to integration costs were sandbagged.
• For this M&A Due Diligence Earnings and Revenue Quality file, read regulatory-approval critical-path calendar against a founder who will not sign a non-compete and write the one fact that would move integration costs were sandbagged for customer-contract risk reviewer.

Recommendation

Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Earnings and Revenue Quality packet (regulatory-approval critical-path calendar after a founder who will not sign a non-compete). The follow-on Earnings and Revenue Quality action is what customer-contract risk reviewer does next: implement the option, assign an owner, and log the missing fact.